|
|
Blood, 1 November 2004, Vol. 104, No. 9, pp. 2655-2660.
Prepublished online as a Blood First Edition Paper on July 1, 2004; DOI 10.1182/blood-2003-09-3032.
 Previous Article | Next Article 
Submitted September 4, 2003
Accepted May 5, 2004
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase I study
Martin A Champagne*, Renaud Capdeville, Mark Krailo, Wenchun Qu, Bin Peng, Marianne Rosamilia, Martine Therrien, Ulrike Zoellner, Susan Blaney, and Mark Bernstein
Hopital Ste-Justine, Montreal, Quebec, Canada
Novartis Pharma AG, Basel, Switzerland
Children's Oncology Group, Arcadia, California, USA
Baylor College of Medicine, Houston, Texas, USA
* Corresponding author; email: martin.a.champagne{at}umontreal.ca.
To determine the optimal dose, dose-limiting toxicities, and pharmacokinetics of imatinib mesylate in children with refractory or recurrent Philadelphia chromosome-positive (Ph+) leukemias. Oral imatinib mesylate was administered daily at dose levels ranging from 260-570 mg/m2 in consecutive 28-day courses of therapy. Serial blood samples for plasma pharmacokinetic studies were collected on days 1 and 8 of course 1. Thirty-one patients between 3-20 years of age with refractory Ph+ leukemias received 479 courses (median 6, range 1-46) of imatinib. The most common toxicities associated with imatinib administration, which occurred in < 5% of courses, were grade 1 or 2 nausea, vomiting, fatigue, diarrhea and reversible increases in serum transaminases. One patient at the 440 mg/m2 dose level had dose-limiting weight gain. There were no other first course dose-limiting toxicities. A maximum tolerated dosage was not defined. Among twelve CML patients evaluable for cytogenetic response, 10 had a complete response and 1 had a partial response. Among ten ALL patients evaluable for morphologic response, seven achieved an M1 and one achieved an M2 bone marrow. Pharmacokinetic analyses revealed that there was marked interpatient variability in the pharmacokinetic parameters. Daily oral imatinib mesylate is well tolerated in children with Ph+ leukemias at doses ranging from 260 to 570 mg/m2. Doses of 260 and 340 mg/m2 provide systemic exposures similar to those of adults who are treated with daily doses of 400 and 600 mg, respectively.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. R. Schultz, W. P. Bowman, A. Aledo, W. B. Slayton, H. Sather, M. Devidas, C. Wang, S. M. Davies, P. S. Gaynon, M. Trigg, et al.
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
J. Clin. Oncol.,
November 1, 2009;
27(31):
5175 - 5181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Koos, J. Paulsson, M. Jarvius, B. C. Sanchez, B. Wrede, S. Mertsch, A. Jeibmann, A. Kruse, O. Peters, J. E.A. Wolff, et al.
Platelet-Derived Growth Factor Receptor Expression and Activation in Choroid Plexus Tumors
Am. J. Pathol.,
October 1, 2009;
175(4):
1631 - 1637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Petain, D. Kattygnarath, J. Azard, E. Chatelut, C. Delbaldo, B. Geoerger, M. Barrois, S. Seronie-Vivien, A. LeCesne, G. Vassal, et al.
Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults
Clin. Cancer Res.,
November 1, 2008;
14(21):
7102 - 7109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Hoffmann, A. Moser, P. Lohse, A. Winkler, B. Binder, P. Sovinz, H. Lackner, W. Schwinger, M. Benesch, and C. Urban
Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation
Blood,
September 1, 2008;
112(5):
1655 - 1657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. Agaram, M. P. Laquaglia, B. Ustun, T. Guo, G. C. Wong, N. D. Socci, R. G. Maki, R. P. DeMatteo, P. Besmer, and C. R. Antonescu
Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors
Clin. Cancer Res.,
May 15, 2008;
14(10):
3204 - 3215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Oudot, M.-F. Auclerc, V. Levy, R. Porcher, C. Piguet, Y. Perel, V. Gandemer, M. Debre, C. Vermylen, B. Pautard, et al.
Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study
J. Clin. Oncol.,
March 20, 2008;
26(9):
1496 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ibrahim, S. S. Daud, Y.-L. Seah, A. E. Yeoh, H. Ariffin, and for the Malaysia-Singapore Leukemia Study Group
Rapid Detection of Prognostically Important Childhood Acute Lymphoblastic Leukemia Chimeric Transcripts Using Multiplex SYBR Green Real-Time Reverse Transcription PCR
Ann. Clin. Lab. Sci.,
January 1, 2008;
38(4):
338 - 343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Fuster, M. Bermudez, A. Galera, M. E. Llinares, D. Calle, and F. J. Ortuno
Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia
Haematologica,
December 1, 2007;
92(12):
1723 - 1724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Pollack, R. I. Jakacki, S. M. Blaney, M. L. Hancock, M. W. Kieran, P. Phillips, L. E. Kun, H. Friedman, R. Packer, A. Banerjee, et al.
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report
Neuro-oncol,
April 1, 2007;
9(2):
145 - 160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
